Keith Humphreys Purchases 775 Shares of Indivior (NASDAQ:INDV) Stock

Indivior PLC (NASDAQ:INDV) Director Keith Humphreys purchased 775 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was bought at an average price of $35.39 per share, with a total value of $27,427.25. Following the transaction, the director owned 5,802 shares of the company’s stock, valued at $205,332.78. This represents a 15.42% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link.

Indivior Price Performance

Shares of INDV stock opened at $35.51 on Friday. The company has a market cap of $4.44 billion, a PE ratio of 38.60 and a beta of 0.75. Indivior PLC has a 1 year low of $7.62 and a 1 year high of $38.00. The stock’s 50 day simple moving average is $34.04 and its two-hundred day simple moving average is $25.73.

Indivior (NASDAQ:INDV) last announced its earnings results on Thursday, October 30th. The company reported $0.72 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.34. Indivior had a negative return on equity of 90.79% and a net margin of 9.83%.The firm had revenue of $314.00 million during the quarter, compared to analysts’ expectations of $257.66 million. Equities research analysts expect that Indivior PLC will post 1.22 EPS for the current year.

Hedge Funds Weigh In On Indivior

A number of hedge funds have recently added to or reduced their stakes in the stock. CWM LLC purchased a new position in shares of Indivior during the third quarter worth approximately $25,000. Quarry LP bought a new position in Indivior in the third quarter worth approximately $26,000. Raymond James Financial Inc. purchased a new position in Indivior during the 2nd quarter worth $26,000. GAMMA Investing LLC increased its holdings in Indivior by 544.6% during the 4th quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock worth $43,000 after purchasing an additional 1,013 shares during the period. Finally, Plato Investment Management Ltd bought a new stake in Indivior during the 3rd quarter valued at $52,000. 60.33% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

INDV has been the subject of several analyst reports. Weiss Ratings restated a “hold (c)” rating on shares of Indivior in a report on Friday, October 31st. Craig Hallum reissued a “buy” rating and issued a $41.00 price objective on shares of Indivior in a research report on Friday, October 31st. Northland Securities set a $40.00 target price on Indivior in a research report on Friday, October 31st. Morgan Stanley reiterated an “overweight” rating and issued a $36.00 price target on shares of Indivior in a report on Wednesday, December 3rd. Finally, Zacks Research raised Indivior from a “hold” rating to a “strong-buy” rating in a research note on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $32.71.

Key Stories Impacting Indivior

Here are the key news stories impacting Indivior this week:

• Positive Sentiment: Management issued full‑year 2026 guidance calling for total net revenue of $1,125M–$1,195M, SUBLOCADE net revenue of $905M–$945M, non‑GAAP operating expenses of $430M–$450M, and adjusted EBITDA of $535M–$575M — guidance implies strong cash generation and SUBLOCADE remains the primary growth driver. Guidance Release
• Positive Sentiment: Multiple insiders (directors David Wheadon, Mark Stejbach, Daniel Ninivaggi, Keith Humphreys and Barbara Ryan) bought shares around ~$35.39 each in early January — combined insider purchases total roughly 4,800–4,900 shares, signaling board‑level conviction. Insider Trades Alert
• Positive Sentiment: Market commentators note INDV is trading near its 52‑week high with room to run, reflecting momentum in the stock and reinforcing positive investor sentiment. Zacks: Near 52‑Week High
• Neutral Sentiment: Wall Street coverage remains constructive (multiple Buy/Strong Buy ratings and raised targets from firms such as Piper Sandler, HC Wainwright); consensus target levels vary and may already be partially reflected in the current price. MarketBeat Analyst Summary
• Negative Sentiment: Despite the positive guidance and insider buying, the stock is trading lower intraday — higher volume suggests some profit‑taking or short‑term repositioning after recent gains. Intraday Trading Note

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.